Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: A preliminary study using a multiplexing approach

Toxicology in Vitro

Volumn 23, Issue 2, 2009, Pages 319-332

  Gerets, H H J ^a   Hanon, E ^a   Cornet, M ^a   Dhalluin, S ^a   Depelchin, O ^a   Canning, M ^a   Atienzar, F A ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Cytotoxicity; Drug development; HepG2 cells; LC50; Multiplexing; Pharmaceutical compounds; Screening

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CASPASE; DOXORUBICIN; FERROUS SULFATE; GLUTATHIONE TRANSFERASE ALPHA; LACTATE DEHYDROGENASE; PHENOBARBITAL; STAUROSPORINE; SULFAMOXOLE; TAMOXIFEN; TERT BUTYL HYDROPEROXIDE; TRITON X 100;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DATA ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; PHARMACEUTICS; PRINCIPAL COMPONENT ANALYSIS; REPRODUCIBILITY;

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; ENZYMES; HEPATOCYTES; HUMANS; MASS SCREENING; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; XENOBIOTICS;

EID: 59249091498     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2008.11.012     Document Type: Article

References (28)

1. Barile F.A., Dierickx P.J., and Kristen U. In vitro cytotoxicity testing for prediction of acute human toxicity. Cell Biology and Toxicology 10 (1994) 155-162
2. Castell J.V., Jover R., Martinez-Jiménez C.P., and Gomez-Lechon M.J. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opinion on Drug Metabolism & Toxicology 2 (2006) 183-212
3. Clarke H., Egan D.A., Heffernan M., Doyle S., Byrne C., Kilty C., and Ryan M.P. Alpha-glutathathione-S-transferase (α-GST) release, an early indicator of carbon tetrachloride hepatotoxicity in the rat. Human & Experimental Toxicology 16 (1997) 154-157
4. Clemedson C., Barile F.A., Chesné C., Cottin M., Curren R., Ekwall B., Ferro M., Gomez-Lechon M.J., Imai K., Janus J., Kemp R.B., Kerszman G., Kjellstrand P., Lavrijsen K., Logemann P., McFarlane-Abdulla E., Roguet R., Segner H., Thuvander A., Walum E., and Ekwall B. MEIC Evaluation of Acute Systemic Toxicity. Part VII. Prediction of Human Toxicity by Results from Testing of the first 30 reference chemicals with 27 further In vitro assays. Alternatives to Laboratory Animals 28 (2000) 161-200
5. Fink S.L., and Cookson B.T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infection and Immunity 73 (2005) 1907-1916
6. Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., and Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chemico-Biological Interactions 168 (2007) 66-73
7. Hagen T.M., Vinarsky V., Wehr C.M., and Ames B.N. (R)-alpha-lipoic acid reverses the age-associated increase in susceptibility of hepatocytes to tert-butylhydroperoxide both in vitro and in vivo. Antioxidants & Redox Signaling 2 (2000) 473-483
8. Hill D.L., Tillery K.F., Rose L.M., and Posey C.F. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Cancer Chemotherapy and Pharmacology 35 (1994) 89-92
9. Kennel P., Pallen C., Barale-Thomas E., Espuña G., and Bars R. Tamoxifen: 28-day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects. Archives of Toxicology 77 (2003) 487-499
10. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates? Nature reviews. Drug Discovery 3 (2004) 711-715
11. Kratz F., Ehling G., Kauffmann H.M., and Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin, an albumin-binding produg of the anticancer agent doxorubicin. Human & Experimental Toxicology 26 (2007) 19-35
12. Krysko D.V., Vanden Berghe T., D'Herde K., and Vandenabeele P. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 44 (2008) 205-221
13. Kutchai H., Geddis L.M., and Farley R.A. Effects of general anaesthetics on the activity of the Na, K-ATPase of canine renal medulla. Pharmacological Research 40 (1999) 469-473
14. Lin J.H.-C., Yang J., Liu S., Takano T., Wang X., Gao Q., Willecke K., and Nedergaard M. Connexin mediates gap junction-independent resistance to cellular injury. The Journal of Neuroscience 23 (2003) 430-441
15. Namour F., Morali A., Ilardo C., Abballe X., Maury F., and Gueant J.L. Comparison between serum alpha-glutathione-S-transferase and aminotransaminases in detecting cytolysis in hepatitis C-infected children. Journal of Pediatric Gastroenterology Nutrition 28 (1999) 534-537
16. O'Brien P.J., Slaughter M.R., Polley S.R., and Kramer K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Laboratory Animals 36 (2002) 313-321
17. O'Brien P.J., Irwin A., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., and Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicology 80 (2006) 580-604
18. Riss T.L., and Moravec R.A. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay and Drug Development Technologies 2 (2004) 51-62
19. Russel W.M.S., and Burch R.L. The Principles of Human Experimental Technique (1959), Methuen, Londen p. 239
20. Sassa S., Sugita O., Galbraith R.A., and Kappas A. Drug metabolism by the human hepatoma cell, HepG2. Biochemical and Biophysical Research Communication 143 (1987) 52-57
21. Scheers E.M., Ekwell B.A., and Dierickx P.J. In vitro long-term cytotoxicity testing of 27 MEIC chemicals on HepG2 cells and comparison with acute human toxicity data. Toxicology In Vitro 15 (2001) 153-161
22. Schmidt E.S., and Schmidt F.W. Glutamate dehydrogenase: biochemical and clinical aspects of an interesting enzyme. Clinica Chimica Acta; International Journal of Clinical Chemistry 173 (1988) 43-55
23. Schoonen W.G.E.J., de Roos J.A.D.M., Westerink W.M.A., and Débiton E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II Mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicology In Vitro 19 (2005) 491-503
24. Schoonen W.G.E.J., de Roos J.A.D.M., Westerink W.M.A., and Débiton E. Cytotoxic effects of 100 reference compounds on HepG2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I. Mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicology In Vitro 19 (2005) 505-516
25. Westerink W.M.A., and Schoonen W.G.E.J. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicology In Vitro 21 (2006) 1581-1591
26. Weyermann J., Lochmann D., and Zimmer A. A practical note on the use of cytotoxicity assays. International Journal of Pharmaceutics 288 (2005) 369-376
27. Xu J.J., Diaz D., and O'Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chemico-Biological Interactions 150 (2004) 115-128
28. Xu S., Sun G., Shen Y., Wei W., Peng W., and Wang H. Antiproliferating and apoptosis induction of paeonol in HepG2 cells. World Journal of Gastroenterology 13 (2007) 250-256